Amgen's Repatha® Proven to Significantly Lower Cardiovascular Event Risk in Clinical Trial Amgen's Repatha® has shown a significant 25% reduction in cardiovascular events, proving its efficacy in high-risk patients in the VESALIUS-CV trial.

Amgen's Repatha® Proven to Significantly Lower Cardiovascular Event Risk in Clinical Trial #None #Amgen #Repatha #PCSK9_Inhibitor